Mark Underwood is President and a Founder of Quincy Bioscience, LLC, a biotechnology company focusing on the diseases of aging. Quincy has identified the fundamental factor in the aging process and age-related diseases such as Alzheimers and Parkinsons. Quincy has also developed a therapeutic compound for the treatment of these neurodegenerative diseases that is currently in the pre-clinical stage of development. The focus of Quincy Biosciences development work revolves around calcium regulation related to aging and age-related disorders and their technology derived from an active compound naturally found in jellyfish.
Quincy has developed products for the dietary supplement marketplace under the brand Prevagen and also is pursuing pharmaceutical applications of their technology. Quincy is growing rapidly and had their first national product launch September 1, 2007, of Prevagen. Quincy Biosciences headquarters are located in Madison, Wisconsin within the University of Wisconsins University Research Park.
In addition to product development, Mark is also an author. He released his first book in the fall of 2007 entitled Gift from the Sea How a protein from jellyfish fights the aging process. Marks own family struggle with the diseases of the brain was one of the inspirations that motivated him to create Prevagen and is described in this book. He explains why brain cells die and the research that proves Prevagen can help.
Mark lives in Madison, Wisconsin, with his wife and their two daughters. Prior to forming Quincy Bioscience Mark was an executive in the contract manufacturing industry and heavily involved in product development for retail product brands. Mark has an academic background in neurochemistry and is the inventor of the technology within Quincy Bioscience.